Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/208556
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Mosteiro, Miguel | - |
dc.contributor.author | Azuara García, Daniel | - |
dc.contributor.author | Alay, Ania | - |
dc.contributor.author | Gausachs Romero, Mireia | - |
dc.contributor.author | Varela, M. | - |
dc.contributor.author | Baixeras, N. | - |
dc.contributor.author | Pijuan, Lara | - |
dc.contributor.author | Ajenjo-Bauza, M. | - |
dc.contributor.author | López Dóriga Guerra, Adriana | - |
dc.contributor.author | Teulé-Vega, Àlex | - |
dc.contributor.author | Solanes, Aleix | - |
dc.contributor.author | Palmero, Ramón | - |
dc.contributor.author | Brenes, Jesús | - |
dc.contributor.author | Jové, M. | - |
dc.contributor.author | Padrones, Susana | - |
dc.contributor.author | Moreno Aguado, Víctor | - |
dc.contributor.author | Cordero, D. | - |
dc.contributor.author | Matias-Guiu, Xavier | - |
dc.contributor.author | Lázaro García, Conxi | - |
dc.contributor.author | Nadal, Ernest | - |
dc.date.accessioned | 2024-03-08T18:24:14Z | - |
dc.date.available | 2024-03-08T18:24:14Z | - |
dc.date.issued | 2023-12-01 | - |
dc.identifier.issn | 2059-7029 | - |
dc.identifier.other | 38070435 | - |
dc.identifier.uri | http://hdl.handle.net/2445/208556 | - |
dc.description.abstract | Background: Targeted next-generation sequencing (NGS) is recommended to screen actionable genomic alterations (GAs) in patients with non-small-cell lung cancer (NSCLC). We determined the feasibility to detect actionable GAs using TruSight™ Oncology 500 (TSO500) in 200 consecutive patients with NSCLC. Materials and methods: DNA and RNA were sequenced on an Illumina® NextSeq 550 instrument and processed using the TSO500 Docker pipeline. Clinical actionability was defined within the molecular tumour board following European Society for Medical Oncology (ESMO) guidelines for oncogene-addicted NSCLC. Overall survival (OS) was estimated as per the presence of druggable GAs and treatment with targeted therapy. Results: Most patients were males (69.5%) and former or current smokers (86.5%). Median age was 64 years. The most common histological type and tumour stage were lung adenocarcinoma (81%) and stage IV (64%), respectively. Sequencing was feasible in most patients (93.5%) and actionable GAs were found in 26.5% of patients. A high concordance was observed between single-gene testing and TSO500 NGS panel. Patients harbouring druggable GAs and receiving targeted therapy achieved longer OS compared to patients without druggable GAs. Conversely, patients with druggable GAs not receiving targeted therapy had a trend toward shorter OS compared with driver-negative patients. Conclusions: Hybrid capture sequencing using TSO500 panel is feasible to analyse clinical samples from patients with NSCLC and is an efficient tool for screening actionable GAs. | - |
dc.format.extent | 10 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Elsevier | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1016/j.esmoop.2023.102197 | - |
dc.relation.ispartof | ESMO Open, 2023, vol. 8, num.6 | - |
dc.relation.uri | https://doi.org/10.1016/j.esmoop.2023.102197 | - |
dc.rights | cc-by-nc-nd (c) European Society for Medical Oncology, CH, 2023 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | - |
dc.source | Articles publicats en revistes (Ciències Clíniques) | - |
dc.subject.classification | Càncer de pulmó | - |
dc.subject.classification | Genòmica | - |
dc.subject.classification | Estudis de viabilitat | - |
dc.subject.other | Lung cancer | - |
dc.subject.other | Genomics | - |
dc.subject.other | Feasibility studies | - |
dc.title | Molecular profiling and feasibility using a comprehensive hybrid capture panel on a consecutive series of non-small-cell lung cancer patients from a single centre | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 743671 | - |
dc.date.updated | 2024-03-08T18:24:14Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
845351.pdf | 449.89 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License